### Efavirenz + emtricitabine + tenofovir

**Section:** 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.5. Fixed-dose combinations of antiretrovirals

#### Indication

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

#### ATC codes:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J05AR06</td>
<td></td>
</tr>
</tbody>
</table>

**ICD11 code:** 1C62.Z

#### INN

Efavirenz + emtricitabine + tenofovir

#### Medicine type

Chemical agent

#### List type

Core

#### Formulations

Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

#### EML status history

First added in 2007 (TRS 946)  
Changed in 2021

#### Sex

All

#### Age

Adolescents and adults

#### Therapeutic alternatives

Efavirenz + lamivudine + tenofovir (ATC codes: J05AR11)

#### Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org. Read more about patents.

#### Wikipedia

Efavirenz + emtricitabine + tenofovir

#### DrugBank

Efavirenz, Emtricitabine, Tenofovir disoproxil

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified a as therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.